Home Blog Page 1471

Key Milestone in Baidu Wenku’s Global Expansion: Ding Yuxi Named Global Ambassador to Expand the Global Reach of Chinese AI

BEIJING, Jan. 21, 2026 /PRNewswire/ — Baidu Wenku, a AI-powered productivity platform and a unit of Baidu, China’s leading artificial intelligence company, today announced the appointment of actor Ding Yuxi as its first Global Ambassador. Following his appointment as Baidu Wenku’s inaugural Brand Ambassador in 2025, the partnership has been expanded, with Ding also serving as Global Ambassador for Oreate AI, Baidu Wenku’s international edition.

BaiduWenku And Oreate AI
BaiduWenku And Oreate AI

As one of China’s most influential young actors, Ding Yuxi has won widespread acclaim among audiences both domestically and internationally for his standout performances in hit series such as Fight for Love and Love Game in Eastern Fantasy. Beyond his proven acting skills and strong professional dedication, his global profile has risen significantly over the past year. He has secured endorsements with international brands including Versace and appeared at the UN Climate Change Conference as a UN-affiliated news correspondent, where his bilingual speech surpassed 18 million views worldwide within 48 hours, underscoring his rapidly growing international appeal.

Meanwhile, Baidu Wenku has received repeated recognition from leading national organizations, including China Industrial Control Systems Cyber Emergency Response Team (CICS-CERT) and Xinhua News Agency. Appointing Ding Yuxi as its Global Ambassador marks a key step in Baidu Wenku’s global expansion, highlighting the platform’s long-term commitment and confidence in engaging users worldwide.

Baidu Wenku’s international expansion is progressing steadily and has already delivered tangible results. Since its debut in 2025, Oreate AI has attracted more than one million users worldwide, spanning over 220 countries and regions. Following a major upgrade in September 2025, the international offering quickly rose to the top of Product Hunt’s daily rankings, drawing strong interest from users across Europe, North America, Southeast Asia, and the Middle East. Its advanced AI capabilities have earned increasing recognition in global markets.

Against this backdrop, Ding Yuxi’s appointment as Baidu Wenku’s Global Ambassador goes beyond a mere fusion of technology and entertainment—it represents a milestone in Baidu’s efforts to bring its AI platforms to a broader global audience. By combining Ding’s rising international influence and Baidu’s technological expertise, the partnership is set to strengthen the global visibility of both Baidu Wenku and Oreate AI, helping users worldwide better discover and engage with AI solutions originating in China.

For more information, please visit wenku.baidu.com.

HD Partners with Pacific Prime to Pioneer AI-Native Healthcare Navigation and Hybrid Access Models in Emerging Southeast Asia

  • Strategic partnership expands access to hybrid healthcare models through AI-driven navigation, connecting Pacific Prime clients to HDmall, HDcare, and Jib AI across Southeast Asia.
  • HD aims to become the AI-native healthcare front door for emerging Southeast Asia, while guiding patients to the right next step and connecting them to real-world care.

BANGKOK, Jan. 21, 2026 /PRNewswire/ — HD, Southeast Asia’s leading AI-Native Healthcare Marketplace & Navigator, today announced a strategic partnership with Pacific Prime, one of the world’s largest international health insurance brokerage firms and employee benefits specialists. The collaboration aims to empower individuals, employers, and insurers in emerging Southeast Asia with more transparent, affordable, and AI-assisted healthcare-access options.

Navigating a New Era of Healthcare Financing

Across emerging Southeast Asia, social-security budget pressures and rising medical inflation are driving both public and private sectors toward more self-funded and hybrid access models. With out-of-pocket spending already accounting for roughly 40% of total healthcare expenditure, consumers are increasingly seeking flexible solutions that blend catastrophic insurance coverage with direct-pay healthcare and AI-driven navigation.

Through this partnership, Pacific Prime’s individual and corporate clients will gain access to both HDmall and HDcare — HD’s flagship platforms that together power the region’s largest AI-native healthcare marketplace. HDmall connects users to over 3,000 healthcare providers and 30,000 health, dental, medical aesthetics, and diagnostic procedures across Thailand and Indonesia, while HDcare enables access to economical co-pay and full-coverage surgical options (incl. hemorrhoid, gastrointestinal, hand-related surgeries), leveraging HD’s network of hospitals and surgeons to deliver high-quality care at up to 20% lower cost. Customers will be able to explore direct-pay healthcare options and covered procedures with greater transparency, convenience, and AI-assisted navigation — bridged by HD’s proprietary AI layer, Jib AI.

AI-Powered Health Navigation for Everyday Care

Pacific Prime’s customers will also gain access to HDmall’s suite of AI-powered health tools and digital health assistants, which help users manage their well-being across areas such as nutrition, women’s health, pediatrics, mental wellness, and preventive care. These AI-native mini-apps make healthcare engagement more proactive and personalized, reinforcing HD’s vision of becoming the AI-native front door to healthcare in Southeast Asia.

Comments from the Founders

Sheji Ho, CEO and Co-Founder of HD, said:

“We are witnessing a structural shift across emerging Southeast Asia’s healthcare systems. As governments face fiscal constraints and insurers adapt to inflationary pressure, consumers are stepping into a new role as self-funded payors. Through this partnership with Pacific Prime, we are enabling a more intelligent, affordable, and accessible way for millions to navigate care — powered by AI and choice.”

Neil Raymond, Founder and CEO of Pacific Prime, commented:

“Our mission has always been to help our global clients make smarter insurance decisions. We believe that the right insurance solutions are flexible, and tailored to the individual and company. After all, there is no one-size-fits-all policy for a workforce that is constantly changing. Partnering with HD allows us to expand that mission beyond insurance — into day-to-day healthcare access. Together, we can help our clients discover new options, make better-informed health decisions, and enjoy a truly connected care experience.”

About HD

HD is the leading AI-Native Healthcare Marketplace & Navigator in emerging Southeast Asia, powering over 3,000 healthcare providers across Thailand and Indonesia. Through its platforms HDmall and HDcare, and its proprietary AI technology Jib AI, HD connects patients to hospitals, clinics, and doctors, enabling more affordable and accessible healthcare for over 500,000 patients to date.

HD is backed by investors including MSD IDEA Studio Asia Pacific, SBI Ven Capital, Partech Partners, FEBE Ventures, M Venture Partners, Ratio Ventures, Orvel Ventures, and TA Ventures.

To learn more about HD, please visit: https://www.hd.care

About Pacific Prime

Established in 2000, Pacific Prime is an award-winning global insurance brokerage and employee benefits specialist that offers individual and corporate insurance solutions. With a USD $1 billion premium under management, Pacific Prime is now the third largest employee benefits broker in the Asia Pacific after acquiring CXA Group’s brokerage arms in 2021. The brokerage has over 1,000 employees and 15 offices worldwide, including Hong Kong SAR, Singapore, China, Thailand, Malaysia, the UAE, Indonesia, the UK, the US, Mexico, the Philippines, and Australia.

To learn more about Pacific Prime, please visit: https://www.pacificprime.com/corporate

 

Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.

Under the agreement, Gene Solutions will provide SOPs, funding, and technical support from its CAP-accredited NGS laboratories in Singapore and Vietnam. Pangea Laboratory will oversee all analytical and clinical validation of Gene Solutions’ tests at its U.S. facilities in Irvine, California. The collaboration is to streamline U.S. readiness for Gene Solutions’ AI-powered multi-omics liquid biopsy technologies within CLIA/CAP quality systems.

Pangea Laboratory and Gene Solutions Teams
Pangea Laboratory and Gene Solutions Teams

“Through our collaboration with Pangea, we’re combining Gene Solutions’ AI-driven multi-omics innovation with world-class U.S. validation expertise,” said Dr. Hoa Giang, Co-founder and Chief Data Science Officer of Gene Solutions. “Together, we aim to deliver affordable, advanced cancer detection, tumor profiling, and monitoring tools.”

The first collaboration phase will prioritize Gene Solutions’ two flagship Next Generation Sequencing (NGS) tests, including:

  • SPOT-MAS™, an AI-powered Multi Cancer Early Detection (MCED) blood test integrating ctDNA epigenomics, fragmentomics, and genomics to detect early cancer signals in a single 10 mL blood draw. The assay’s development and performance have been assessed across 10 major cancer types and 75 subtypes.
  •  K-4CARE™, a dual‑function precision oncology assay combining comprehensive genomic and transcriptomic profiling with Molecular Residual Disease (MRD) detection to guide targeted therapy selection and deliver longitudinal ctDNA-MRD monitoring insights.

John Moore, CEO of Pangea Laboratory, added: “Pangea is pleased to support the advancement of SPOT-MAS and K-4CARE in the U.S. market which are complementary to Pangea’s Bladder CARE™ assay, for the early detection of Bladder Cancer. Our validation platform is designed specifically for innovative LDTs, and we look forward to helping clinicians and patients benefit from these technologies.”

From left to right: John Moore, CEO of Pangea Laboratory, and Keng-Hou Hsu, Chief Financial Officer of Gene Solutions
From left to right: John Moore, CEO of Pangea Laboratory, and Keng-Hou Hsu, Chief Financial Officer of Gene Solutions

About Pangea Laboratory
Founded in 2014, Pangea Laboratory is a CLIA-certified, CAP‑accredited diagnostics company specializing in high complexity testing and validation services for innovative assays, including Next Generation Sequencing and molecular diagnostics. For more information, visit https://pangealab.com.

About Gene Solutions
Gene Solutions is a global biotechnology company headquartered in Singapore with a mission to make advanced genomic solutions accessible and affordable. Leveraging multi-omics, NGS, and AI, the company offers a portfolio including multicancer early detection (SPOT-MAS) and comprehensive tumor profiling with ctDNA monitoring (K-TRACK, K-4CARE). Gene Solutions operates CAP-accredited NGS laboratories and has delivered millions of genetic tests worldwide since 2017. For more information, visit www.genesolutions.com and follow the company on LinkedIn and Facebook.

Important Disclaimer
Some tests may be offered as LDTs in CLIA-certified, CAP‑accredited laboratories; availability and institutional policies vary by state and health system. Results are intended for professional use only. SPOT‑MAS is recommended for adults at elevated cancer risk and should complement guideline recommended screening; it does not detect all cancers.

This release includes forward‑looking statements subject to risks and uncertainties; neither Gene Solutions nor Pangea Laboratory has any obligation to update these statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. (Regulatory context for LDTs: following the March 31, 2025, federal district court vacatur, FDA issued a final rule implementing the vacatur and reverting to prior regulatory text; CLIA/CAP oversight applies to LDT services.)

Digital Turbine Appoints Sea Yen Ong as Regional Vice President, Sales, APAC

Seasoned industry leader to drive brand and agency growth across APAC, as Digital Turbine continues to expand its presence in the region

SINGAPORE, Jan. 21, 2026 /PRNewswire/ — Digital Turbine (NASDAQ: APPS), the global leader in growth solutions for the mobile ecosystem, today announced the appointment of Sea Yen Ong as Regional Vice President, Sales, APAC. Based in Singapore, Sea Yen will lead Digital Turbine’s brand and agency strategy across the region, supporting the company’s continued growth and investment in APAC.

Sea Yen Ong, Regional Vice President, Sales, APAC, Digital Turbine
Sea Yen Ong, Regional Vice President, Sales, APAC, Digital Turbine

Sea Yen joins Digital Turbine at an important time of change, as media teams and agency networks streamline operations and recalibrate for performance and efficiency, heading into 2026. In this role, he will partner closely with agencies and marketers across APAC to drive stronger brand outcomes through Digital Turbine’s unique mobile ecosystem and premium experiences.

Prior to joining Digital Turbine, Sea Yen held senior leadership roles at TikTok and Spotify, partnering closely with advertisers to drive market growth. Most recently, he served as Country General Manager at TikTok, where he led commercial strategy and worked closely with agencies and advertisers to support growth across markets.

At DT, Sea Yen will lead regional teams as they scale mobile campaigns across APAC, harnessing Digital Turbine’s exclusive partnerships with leading carriers, OEMs, and 82K+ SDK-integrated apps that connect brands to audiences in premium, immersive environments that drive real results.

“APAC continues to be a significant growth market for Digital Turbine, and we are investing to build market coverage and deepen strategic relationships with brands and agencies. Yen’s appointment reflects our continued commitment to the region,” said Jon Hudson, SVP of Global Sales at Digital Turbine. “Yen brings the rare combination of global platform leadership, agency credibility, and commercial execution. He knows how to build markets and understand what it takes to drive real outcomes for advertisers. We’re thrilled to have him on board. “

“APAC is one of the most dynamic and nuanced advertising regions in the world, and what brands need from mobile is evolving. Digital Turbine offers a differentiated way for brands to connect with consumers through meaningful mobile experiences,” said Sea Yen. “I’m excited to join the team and work with our partners across APAC to unlock new opportunities, drive stronger outcomes, and continue building impactful mobile solutions for brands and agencies across the region.”

About Digital Turbine
Digital Turbine (NASDAQ: APPS) powers superior mobile consumer experiences and results for the world’s leading telcos, advertisers, and publishers. Its end-to-end platform uniquely simplifies their partners’ ability to supercharge awareness, acquisition, and monetization – connecting them with more consumers, in more ways, across more devices. Digital Turbine is headquartered in North America, with offices around the world. www.digitalturbine.com

Media Contact
Daniel Gal
daniel.gal@digitalturbine.com

Agoda and Mastercard Collaborate to Modernize Loyalty Programs with Flexible Travel Rewards

Agoda’s global travel inventory now available through Global Redemption Suite, enabling banking to deliver loyalty with instant, personalized travel rewards

SINGAPORE, Jan. 21, 2026 /PRNewswire/ — Digital travel platform Agoda and Mastercard have joined forces to launch a modular travel redemption solution that empowers banks to modernize their loyalty programs and offer more meaningful benefits to cardholders. This collaboration integrates Agoda’s extensive global travel inventory into Mastercard’s Global Redemption Suite, giving cardholders direct, real-time access to flexible travel rewards and more ways to redeem points for memorable experiences.

Through this collaboration, banks connected to Mastercard’s rewards ecosystem can embed the Agoda-powered travel redemption solution into their own loyalty programs. This enables banks to quickly deliver a branded experience, where points can be redeemed instantly and applied directly to Agoda’s global inventory of accommodations and flights. For cardholders, the result is a digital-first travel, seamless travel rewards experience tailored to diverse lifestyles.

As loyalty programs evolve toward personalization and partnerships, this launch reflects a growing trend: ecosystems that deliver value beyond traditional rewards. By connecting banks with Agoda’s inventory through Mastercard’s trusted network, the offering delivers flexibility and choice—key drivers of modern loyalty.

“Across the industry, many loyalty points still go unused because customers don’t see enough real value or flexibility in how they redeem. By joining forces with Mastercard, we’re helping banks close that value gap with travel rewards that are immediate, intuitive, and genuinely useful. By embedding Agoda’s interfaces, technology, and global inventory into Mastercard’s solution, cardholders can use their points the way they want, on their timelines, while banks gain a simple, scalable way to modernize loyalty and drive deeper engagement,” said Damien Pfirsch, Chief Commercial Officer at Agoda.

Industry research underscores this shift. According to the Skift State of Travel 2025 report, most travelers join loyalty programs for practical benefits such as discounted travel, easier earning and redemption, and premium access—factors that directly influence booking decisions and reinforce loyalty. Similarly, Arrivia’s 2025 Loyalty Landscape Report reveals that 84% of loyalty programs plan to expand their travel benefits this year, as consumers increasingly prioritize meaningful, experience-led rewards. This collaboration enables banks to meet these evolving expectations with travel rewards that drive measurable engagement including higher redemption frequency and active card rates.

“At Mastercard, we are transforming loyalty into a digital-first, hyper-personalized experience. By enabling effortless redemption with Agoda, we’re creating a connected ecosystem that delivers convenience and meaningful value at every touchpoint. Together, we’re shaping a future where loyalty is dynamic, data-driven, and seamlessly integrated into the moments that matter most,” said Matthew Driver, Executive Vice President, Services, Asia Pacific.

This launch marks a significant step toward the future of loyalty—where flexibility, instant access, and meaningful experiences define value. By connecting banks, cardholders, and travel in one seamless ecosystem, Agoda and Mastercard are setting a new standard for choice and relevance in every journey.

AM Group Signs Landmark MoU with Uttar Pradesh Government to set up GW scale AI Compute Hub enabling Democratization of AI from Electron Agents to Intelligent Tokens

DAVOS, Switzerland, Jan. 21, 2026 /PRNewswire/ — AM Group, the leading energy transition platform backed by the founders of Greenko Group, today announced the signing of a Memorandum of Understanding (MoU) with Invest UP, Government of Uttar Pradesh to establish a 1 GW (Gigawatt) High Performance Compute Hub to serve global AI workloads.

AMG will establish an AI Infrastructure hub in the Greater Noida region in Uttar Pradesh with a total investment of ~ USD 25 Billion. This grand scale project will be developed in a phased manner with first capacity coming up in 2028 and full 1 GW capacity targeted to come up by 2030. This partnership underscores AM Group’s commitment to building a sustainable, carbon-neutral intelligent economy solutions and aligns with Uttar Pradesh’s vision to become India’s premier AI hub.

This project will be a multi-billion investment for the set-up of GW scale infrastructure with ~500,000 latest high-performance chipsets and will be one of the largest investments in country to-date aligned with the Indian Government’s Viksit Bharat 2047 vision to accelerate the expansion of AI-driven services.

Powering the Future of AI and High-Performance Compute

As India’s demand for high-performance computing (HPC) and Artificial Intelligence (AI) workloads surges, this facility will be designed to meet the requirements of global hyperscalers, frontier labs, enterprises and India’s sovereign AI initiatives at scale and in speedy manner using carbon-free energy.

AMG AI labs, with its vision of Democratizing AI, is developing end-to-end value chain from efficient on-demand electron to intelligent token. These intelligent tokens form key inputs for customized models & applications across sectors including energy, healthcare, sovereign clouds, manufacturing, automotive, media & gaming amongst others.

This HPC compute capability will also enable chipset access to wider Indian developer community to fast track and develop AI solution stacks for global and domestic usage.

The AI hub will feature:

  • Scalable Infrastructure: Phased rollout with the first capacity being operational by 2028, scaling to the full 1 GW by 2030.
  • Strategic Location: Utilizing Uttar Pradesh’s robust industrial corridors and favourable Data Center Policy to provide low-latency and high reliable connectivity to growing digital markets.
  • Green Energy Integration: Leveraging AMG’s leadership in renewable energy, the facility will be powered by 24/7 carbon-free energy solutions, including wind, solar, and pumped storage.

A Catalyst for Economic Growth

The MoU was exchanged in the presence of senior government officials and the leadership team of AMG at World Economic Forum at Davos. The project is expected to attract significant foreign direct investment (FDI) and generate thousands of high-skilled jobs in the region, fostering a local ecosystem for hardware manufacturing, software development, and specialized cooling technologies.

“Evolution of global AI ecosystem with intentionality, intelligence and adaptability will be a pivotal tool for current & future generations. AMG AI labs focus on valorising electron agents into intelligent tokens is a natural extension of our technology-first approach to our businesses as the global AI ecosystem races towards Physical AI Solutions,” said Anil Chalamalasetty, Group Chairman, AM Group.

“By combining 1 GW of compute capacity with our 24/7 green power solutions, we are not just building a data center; we are creating a sustainable template for the future of global AI infrastructure with the support from State of Uttar Pradesh,” added Mahesh Kolli, Group President, AM Group.

About AM Group

AMG is promoted by founders of Greenko Group, which is among India’s leading renewable energy conglomerates. AMG is building globally differentiated platforms across molecules, materials and AI technologies to enable industrial decarbonization & competitive tokenization at scale.

Greenko will be a 50 GW Energy Infrastructure platform with presence across 20+ states across solar, wind, hydro and energy storage projects. Greenko is building world’s first interconnected energy storage solution with 100 GWh storage capacity across the country.

AMG is developing low-carbon ammonia projects across multiple locations in India with a goal to reach 5 Mtpa of green ammonia capacity. It’s currently under construction 1 Mtpa green ammonia plant will be one of the world’s largest RFNBO compliant green ammonia facilities, supporting efforts to achieve net zero targets both in India and global markets.

AMG is also developing production capabilities for other net zero molecules and chemicals including green caustic soda, e-methanol, olefins & biofuels including sustainable aviation fuel for decarbonization in hard to abate industries.

AMG Metals & Materials is setting up a 1 MTPA Green Aluminium production plant as part of wider green materials offering.

Media Contact for AM Group: Sheela Panicker, enright@enrightpr.com

ChooChoo, an AI Interactive Reading Toy Built on RiseLink Edge Intelligence, Featured at CES 2026 and Highlighted Across National and Local Media

LAS VEGAS, Jan. 21, 2026 /PRNewswire/ — ChooChoo, an AI-powered interactive reading companion designed to support early childhood language development, was featured at CES® 2026, where it drew attention for its research-backed approach to helping children learn through conversation—powered by edge AI and ultra-low-power connectivity from RiseLink Technologies.

During CES week, ChooChoo was showcased across multiple media outlets, including KLAS News Now (CBS Las Vegas), WBTS (NBC Boston), KSNV-TV (NBC Las Vegas), and the nationally syndicated Anna & Raven Show, reflecting growing interest in how edge AI can be applied thoughtfully and responsibly to children’s learning products.

A Research-Backed Approach to Early Reading

ChooChoo helps children build language and early reading skills through interactive read-aloud, rather than passive listening. Its design is inspired by interactive (dialogic) reading methods from Yale’s early childhood language development research, which have been shown to significantly improve children’s language abilities in as little as one month when used consistently.

ChooChoo was created by Dr. Diana Zhu (Yale PhD), combining academic research with warm, playful product design for children ages 3–6. Through natural conversation and adaptive storytelling, ChooChoo:

  • Engages children in back-and-forth dialogue during stories
  • Introduces and reinforces vocabulary in meaningful context
  • Supports comprehension, emotional language, and confidence
  • Adapts to each child’s pace, interests, and learning progress

An optional parent app allows caregivers to view reading progress, vocabulary learned, and how the system adapts over time.

Powered by RiseLink Edge AI: Low Latency, Ultra-Low Power, and Privacy by Design

ChooChoo is built on RiseLink’s edge AI and wireless connectivity platform, including ultra-low-power AI SoCs such as the BK7259-class chips, designed specifically for always-on, edge-AI devices.

By performing key intelligence directly on the device, RiseLink’s chips enable:

  • Low-latency responses, critical for natural, frustration-free child interaction
  • Ultra-low power consumption, extending battery life for daily use
  • Privacy and security by design, with sensitive interactions processed locally rather than continuously streamed to the cloud

This edge-first architecture allows ChooChoo to feel responsive and “alive,” while giving parents confidence that their child’s data and interactions are handled securely.

Proven Edge AI Technology at Global Scale

RiseLink’s edge AI and connectivity chips are already deployed at massive global scale, powering billions of connected devices worldwide across smart home, consumer electronics, and intelligent hardware categories. The company ships 200M+ units annually in AI-native device scenarios, demonstrating production-grade reliability and maturity.

RiseLink is a long-term silicon partner to leading global brands across consumer electronics and smart devices, including LG, Samsung, Midea, and Hisense, bringing industrial-grade performance, security, and efficiency to next-generation products—including AI-powered toys.

Redefining AI-Powered Toys

ChooChoo represents a new generation of AI-native toys—products that move beyond scripted playback to become responsive, adaptive companions grounded in research, safety, and real-world reliability.

Its debut at CES 2026, combined with national and local media coverage, underscores how edge AI and ultra-low-power chip design can unlock meaningful, child-safe learning experiences—without compromising privacy, responsiveness, or battery life.

Dr. Diana Zhu appears with ChooChoo in the CES® 2026 broadcast office, where CES spokespersons present the year’s featured products. ChooChoo was selected as one of fewer than 50 products highlighted at CES 2026 for its research-driven approach to early childhood learning.
Dr. Diana Zhu appears with ChooChoo in the CES® 2026 broadcast office, where CES spokespersons present the year’s featured products. ChooChoo was selected as one of fewer than 50 products highlighted at CES 2026 for its research-driven approach to early childhood learning.

 

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

  • Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insilico is eligible to receive up to USD 66 million in upfront and milestone payments.
  • Insilico will lead the IND submission and Phase 1 clinical trial of ISM8969, after which Hygtia Therapeutics will take responsibility for further clinical development, regulatory filings, and commercialization.
  • ISM8969, an orally available, brain penetrant NLRP3 inhibitor discovered using Insilico’s generative AI platform Chemistry42, has demonstrated strong efficacy, favorable safety, and robust blood-brain barrier (BBB) penetration in preclinical studies.

CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development collaboration agreement for Insilico’s ISM8969 program. Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.

Under the terms of the agreement, Insilico grants Hygtia Therapeutics 50% worldwide rights to research, develop, register, manufacture, and commercialize ISM8969. In return, Insilico is eligible to receive upfront and milestone payments totaling up to USD$66 million, including an initial upfront payment of USD$10 million expected within 30 days of the agreement’s effective date.

Reflecting the joint commitment to the program’s success, Insilico will lead the initial clinical development, including IND submission and execution of the Phase 1 clinical trial for the Parkinson’s disease indication. Hygtia Therapeutics will assume leadership of subsequent global clinical studies, regulatory submissions, and commercialization activities.

The NLRP3 inflammasome is a critical component of the innate immune system. Its aberrant activation is increasingly recognized as a key driver of neuroinflammation, contributing to the pathology of multiple neurodegenerative diseases, including Parkinson’s disease (PD) and Alzheimer’s disease (AD). While NLRP3 inhibition holds significant therapeutic promise, there are currently no approved therapies that directly and specifically target NLRP3, accentuating the strategic need for in-depth R&D advancement in this area.

ISM8969, a potential best-in-class NLRP3 inhibitor, was discovered and optimized using Chemistry42, Insilico’s proprietary generative chemistry engine. Preclinical data has demonstrated the molecule’s robust efficacy, favorable safety profile and marked anti-inflammatory activity in various disease models. Importantly, ISM8969 achieves desirable blood–brain barrier (BBB) penetration, a critical advantage that enables it to cross the natural protective barrier between the central nervous system and the bloodstream, and holds great promise for treating neuroinflammation-related diseases.

Based on promising preclinical data, Insilico nominated ISM8969 as the preclinical candidate and has conducted extensive evaluations of the molecule across multiple neurological disease models.

“Targeting neuroinflammation via NLRP3 represents a scientifically sound and high-potential approach to treating neurodegenerative and age-related diseases,” said Ren Feng, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “However, developing a safe molecule with good blood-brain barrier penetration remains a formidable obstacle for drug developers. Through our generative AI platform, we have designed a molecule specifically engineered to overcome this barrier. We are pleased to partner with Hygtia Therapeutics, We believe that through our combined efforts, we can accelerate its clinical progress to address significant unmet medical needs.”

Hygtia Therapeutics stated: “We are delighted to enter this strategic collaboration with Insilico Medicine, which marks a pivotal step in our global strategy.This partnership aligns with our strategy to expand our innovative neuroscience pipeline through high-quality assets.This BBB-penetrating NLRP3 inhibitor directly reflects our commitment to creating globally competitive innovations. We will advance its development through a collaborative alliance, uniting our strengths to deliver better therapeutic solutions worldwide.”

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

About Hygtia Therapeutics

Hygtia Therapeutics, an innovative biotechnology company incubated by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, was founded in August 2025 with a focus on autoimmune diseases and related areas. The company is committed to a global product strategy, introducing and developing pipelines with “best-in-class” potential worldwide. Through efficient and effective R&D capabilities, it aims to provide patients with breakthrough treatment options.

Forward-Looking Statements:

This press release contains forward-looking statements relating to the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial performance. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “visions”, “schedule” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company at the time of this press release in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain.  Actual results, performance and financial condition may differ materially from the Company’s expectations. 

All of the forward-looking statements made in this press release are qualified by these statements. Consequently, the inclusion of forward-looking statements in this press release should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements. 

The Company, its Board, the employees and the agents of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this press release; and (b) no liability for any losses in the event that any of the forward-looking statements do not materialise or turn out to be incorrect.